Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRSNASDAQ:AKTXNYSE:CYBNNASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.38+3.8%$1.51$0.95▼$5.17$149.43M0.531.19 million shs440,602 shsAKTXAkari Therapeutics$1.44+5.1%$1.16$0.85▼$4.40$38.29M0.5732,859 shs27,826 shsCYBNCybin$6.72-1.3%$7.01$4.81▼$14.44$144.33M0.61237,632 shs290,377 shsPBYIPuma Biotechnology$3.18+4.6%$3.12$2.23▼$5.26$157.76M1.34442,155 shs545,225 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+3.76%+15.97%-9.80%-42.26%+14.05%AKTXAkari Therapeutics+5.11%-0.89%+19.40%+6.67%-6.49%CYBNCybin-1.32%-2.89%+5.99%-32.67%+1,820.00%PBYIPuma Biotechnology+4.61%+4.95%+7.43%+4.61%-37.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics3.1423 of 5 stars3.63.00.00.03.31.71.3AKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACYBNCybin1.595 of 5 stars3.50.00.00.00.00.81.3PBYIPuma Biotechnology3.8022 of 5 stars3.52.00.00.01.93.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.67745.41% UpsideAKTXAkari Therapeutics 0.00N/AN/AN/ACYBNCybin 3.00Buy$86.001,179.76% UpsidePBYIPuma Biotechnology 3.00Buy$7.00120.13% UpsideCurrent Analyst Ratings BreakdownLatest AKTX, PBYI, CYBN, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025ACRSAclaris TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight3/13/2025CYBNCybinGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.003/7/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$15.003/4/2025ACRSAclaris TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/28/2025PBYIPuma BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.002/13/2025CYBNCybinHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$190.00 ➝ $150.002/12/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $73.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M7.98N/AN/A$2.22 per share0.62AKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/APBYIPuma Biotechnology$230.47M0.68$0.76 per share4.19$1.12 per share2.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.51N/AN/AN/A-136.65%-40.26%-31.71%5/6/2025 (Estimated)AKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/15/2025 (Estimated)CYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/APBYIPuma Biotechnology$21.59M$0.616.638.37N/A9.56%41.60%10.71%5/8/2025 (Estimated)Latest AKTX, PBYI, CYBN, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PBYIPuma Biotechnology$0.02N/AN/AN/A$44.55 millionN/A5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19N/AN/AN/A$3.55 millionN/A2/27/2025Q4 2024PBYIPuma Biotechnology$0.10$0.39+$0.29$0.39$52.50 million$59.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A7.037.03AKTXAkari TherapeuticsN/A0.290.29CYBNCybinN/A24.2424.24PBYIPuma Biotechnology0.461.421.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%AKTXAkari Therapeutics5.06%CYBNCybin17.94%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%AKTXAkari Therapeutics38.90%CYBNCybin15.00%PBYIPuma Biotechnology23.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million66.86 millionOptionableAKTXAkari Therapeutics926.59 million16.25 millionNot OptionableCYBNCybin5021.48 million17.96 millionNot OptionablePBYIPuma Biotechnology20049.61 million37.45 millionOptionableAKTX, PBYI, CYBN, and ACRS HeadlinesRecent News About These CompaniesPuma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should KnowApril 30 at 1:00 PM | zacks.comEr-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer PatientsApril 30 at 6:00 AM | globenewswire.comPuma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025April 28 at 3:03 PM | businesswire.comStockNews.com Upgrades Puma Biotechnology (NASDAQ:PBYI) to "Strong-Buy"April 27, 2025 | americanbankingnews.comPuma Biotechnology (NASDAQ:PBYI) Upgraded to Strong-Buy at StockNews.comApril 27, 2025 | marketbeat.comPuma Biotechnology (PBYI) to Release Quarterly Earnings on ThursdayApril 26, 2025 | marketbeat.comPuma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial ResultsApril 24, 2025 | businesswire.comEversept Partners LP Decreases Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)April 24, 2025 | marketbeat.comPuma Biotechnology (PBYI) Expected to Announce Earnings on ThursdayApril 24, 2025 | americanbankingnews.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?April 23, 2025 | zacks.comIs the Options Market Predicting a Spike in Puma Biotechnology Stock?April 21, 2025 | zacks.comPuma Biotechnology (NASDAQ:PBYI) Upgraded to "Strong-Buy" at StockNews.comApril 18, 2025 | marketbeat.comKennedy Capital Management LLC Buys 216,329 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)April 16, 2025 | marketbeat.comPuma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline PotentialApril 11, 2025 | seekingalpha.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | businesswire.comWINTON GROUP Ltd Sells 270,739 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)April 2, 2025 | marketbeat.comPuma SE: Undervalued With Tailwinds AheadMarch 31, 2025 | seekingalpha.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?March 27, 2025 | finance.yahoo.comPUMA SE: This Is The Right Time To BuyMarch 21, 2025 | seekingalpha.comPuma Biotechnology Stock Rises 35% in 6 Months: Here's WhyMarch 20, 2025 | msn.comPuma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKTX, PBYI, CYBN, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.38 +0.05 (+3.76%) As of 04/30/2025 04:00 PM EasternAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Akari Therapeutics NASDAQ:AKTX$1.44 +0.07 (+5.11%) As of 04/30/2025 03:59 PM EasternAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Cybin NYSE:CYBN$6.72 -0.09 (-1.32%) As of 04/30/2025 04:00 PM EasternCybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Puma Biotechnology NASDAQ:PBYI$3.18 +0.14 (+4.61%) As of 04/30/2025 04:00 PM EasternPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
